← Leaderboards
Jennifer Balfour
University Of Minnesota Twin Cities
$109,530
Attributed
$109,530
Total exposure
15
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $46.9K · FY2005–06$50K$37.5K$25K$12.5K$0
'05
'06
Funding mix
By agency
NIH$109,530 · 15
By mechanism
M01$109,530 · 15
Top collaborators
No co-investigators on record.
Most similar at University Of Minnesota Twin Cities
Same institution · by research overlap
- Courtney V. Fletcher$8,186,840
- Yun Qiu$5,397,385
- Stella Margaret Davies$7,181,470
- Edward Chen$284,690
- Gregg B Fields$11,773,691
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman Therapy EvaluationHiv InfectionsHuman SubjectCombination ChemotherapyPhoton AbsorptiometryLipid MetabolismDrug InteractionsAids TherapyPatient Oriented ResearchBody CompositionDrug Screening /EvaluationAntiaids AgentProtease InhibitorCholesterolTriglyceridesDietary SupplementsBlood LipidCombination TherapyClinical TrialsGlucose Tolerance TestDiet TherapyNutrition Related TagClinical Trial Phase Iii
Grant awards (15)
ACTG A5142: A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LOPINAVIR/RITONAVI$15,673
M01 · FY2006 · RR · contact PI
ACTG A5163: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ON$9,899
M01 · FY2006 · RR · contact PI
AIDS CLINICAL TRIAL GROUP A5079$2,478
M01 · FY2006 · RR · contact PI
ACTG A5142: A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LOPINAVIR/RITONAVI$22,974
M01 · FY2005 · RR
ACTG A5079$11,028
M01 · FY2005 · RR
ACTG A5163: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ON$5,514
M01 · FY2005 · RR
ACTG A5124S: VISCERAL ADIPOSE TISSUE SUBSTUDY AND ACTG A5125S: BONE DENSITY SUBS$3,675
M01 · FY2005 · RR
ACTG A5165: A PHASE I/II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUD$1,840
M01 · FY2005 · RR
ACTG A5148: A PILOT STUDY OF THE SAFETY, EFFICACY, AND TOLERABILITY OF EXTENDED-$1,839
M01 · FY2005 · RR
ACTG A5142: A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LOPINAVIR/RITONAVI$12,497
M01 · FY2004 · RR
ACTG A5163: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ON$6,729
M01 · FY2004 · RR
ACTG A5148: A PILOT STUDY OF THE SAFETY, EFFICACY, AND TOLERABILITY OF EXTENDED-$5,768
M01 · FY2004 · RR
Clinical Trial of Anti-HIV-1 Activity of Naltrexone$3,845
M01 · FY2004 · RR
ACTG A5079$2,887
M01 · FY2004 · RR
ACTG A5082 Metformin and Rosiglitazone in HIV-infected Subjects$2,884
M01 · FY2004 · RR